A manufacturer-funded study found a significant decrease in annual total medical costs in patients with overweight/obesity ...

The costs for 806 patients with overweight or obesity and heart failure were analyzed in one study. For those patients, the average total medical costs dropped from $29,654 before treatment began to ...

Ministers have been urged to ditch "gimmicks and soundbites" while addressing the soaring cost of obesity to the NHS.

Millions in South Africa face rising diabetes treatment costs and limited access to insulin pens, sparking protests.

Results demonstrated the mean total medical costs per patient per year decreased significantly after patients began ...

Today it is happening again with GLP1 agonists like Semaglutide with the brand names of Wegovy ... He is concerned about the ...

So what is semaglutide and who uses it in India? Semaglutide belongs to the class of drugs called Glucagon-like peptide-1 ...

Semaglutide shows promise in treating knee osteoarthritis by reducing pain and weight, offering a safe alternative to ...

In the ESSENCE trial, semaglutide improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...

A new study has shed light on the health risks faced by people who stop using weight-loss medications Ozempic or Wegovy.